Improvement of Erythropoietin-Induced Hypertension in Hemodialysis Patients Changing the Administration Route

REFERENCES

• Anagnostou A, Lee ES, Kessimian N, Levison R, Steiner M. Erythropoietin has a mitogenic and positive effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978–5982.
   PubMed Web of Science ®Google Scholar
• Bommer J, Samtleben W, Koch KM, Baldamus CA, Grützmacher P, Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. Contr Nephrol 1989; 76: 149–158.
   PubMedGoogle Scholar
• Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 1990; 3: 947–955.
   PubMed Web of Science ®Google Scholar
• Cheng IK, Cy C, Chan MK, Yu L, Fang GX, Wei D. Correction of anemia in patients on continous ambulatory peritonel dialysis with subcutaneous recombinant erythropoietin twice a week: a long term study. Clin Nephrol 1991; 35: 207–212.
   PubMed Web of Science ®Google Scholar
• Eidemak I, Friedberg MO, Ladefoged SD, Lokkegaard H, Pedersen E, Skielboe M. Intravenous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplant 1992; 7: 526–529.
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–163.
   PubMed Web of Science ®Google Scholar
• Gotch FA, Keen ML. Care of the patient on hemodialysis. In Cogan MG, Gavoroy MR (eds.). Introduction to Dialysis. New York: Churchill Livingstone, 1985: 73–143.
   Google Scholar
• Granolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S. Experience with daily self-administered subcutaneous erythropoietin. Contr Nephrol 1989; 76: 143–148.
   PubMedGoogle Scholar
• Lai KN, Lui SF, Leung JCK, Law E, Nicholls MG. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continious ambulatory peritoneal dialysis. Nephron 1991; 57: 394–400.
   PubMed Web of Science ®Google Scholar
• Lim VS, Kircher PT, Fangman J, Richmond J, DeGowin RL. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 1989; XIV: 496–506.
   Google Scholar
• McDougall IC, Davies ME, Hutton RD, et al. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 950–955.
   PubMed Web of Science ®Google Scholar
• McDougall IC, Roberts DE, Coles GA, Williams JD. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99–113.
   PubMed Web of Science ®Google Scholar
• McMahon LP, Dawborn JK. Experience with a low dose intravenous and subcutaneous administration of recombinant human erythropoietin. Am J Nephrol 1990; 10: 404–408.
   PubMed Web of Science ®Google Scholar
• Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic hemodialysis patients. Pharmacol Toxicol 1990; 66: 83–86.
   PubMedGoogle Scholar
• Pascual J, Teruel JL, Marcén R, Liaño F, Ortuño J. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 1992; 15: 353–356.
   Web of Science ®Google Scholar
• Raine AEG, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; XVIII: 76–83.
   Google Scholar
• Samtleben W, Baldamus CA, Bommer J, et al. Blood pressure changes during treatment with recombinant human erythropoietin. Contr Nephrol 1988; 66: 114–122.
   PubMedGoogle Scholar
• Stevens JM, Auer J, Strong CA, et al. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6: 487–494.
   PubMed Web of Science ®Google Scholar
• Stockenhuber F, Loibl U, Jahn C, Manker W, Meissl F, Balcke P. Intravenous versus subcutaneous application of erythropoietin in patients on regular dialysis treatment and CAPD. Nephrol Dial Transplant 1989; 4: 478–479.
   Google Scholar
• Tomson CRV, Feehally J, Walls J. Crossover comparison on intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 129–132.
   PubMed Web of Science ®Google Scholar
• Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: Comparison between intravenous and subcutaneous administration. Nephron 1991; 57: 485–486.
   PubMed Web of Science ®Google Scholar